Abstract
Patients with systemic mastocytosis are rare, constitute a heterogenous clinical entity and some may not require treatment until long after diagnosis. However, most patients who present with disabling symptoms, organ involvement and fulfill B or C findings as outlined in the 2008 WHO classification need treatment. This review on interferon treatment in systemic mastocytosis documents an effect of this biological agent in some patients with mastocytosis. However, the place of interferon-α, as mono- or combination therapy, in the treatment algorithm may only be definitely established in multicenter studies, which are based on the principles of controlled clinical trials.
Keywords: Mast cells, mastocytosis, interferon, classification, treatment, review
Current Drug Targets
Title: Interferon-α Treatment in Systemic Mastocytosis
Volume: 12 Issue: 3
Author(s): Ole Weis Bjerrum
Affiliation:
Keywords: Mast cells, mastocytosis, interferon, classification, treatment, review
Abstract: Patients with systemic mastocytosis are rare, constitute a heterogenous clinical entity and some may not require treatment until long after diagnosis. However, most patients who present with disabling symptoms, organ involvement and fulfill B or C findings as outlined in the 2008 WHO classification need treatment. This review on interferon treatment in systemic mastocytosis documents an effect of this biological agent in some patients with mastocytosis. However, the place of interferon-α, as mono- or combination therapy, in the treatment algorithm may only be definitely established in multicenter studies, which are based on the principles of controlled clinical trials.
Export Options
About this article
Cite this article as:
Weis Bjerrum Ole, Interferon-α Treatment in Systemic Mastocytosis, Current Drug Targets 2011; 12 (3) . https://dx.doi.org/10.2174/138945011794815293
DOI https://dx.doi.org/10.2174/138945011794815293 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Growth and Trophic Factors, pH and the Na+/H+ Exchanger in Alzheimers Disease, Other Neurodegenerative Diseases and Cancer: New Therapeutic Possibilities and Potential Dangers
Current Alzheimer Research Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design Activated Cancer Therapy Using Light and Ultrasound - A Case Series of Sonodynamic Photodynamic Therapy in 115 Patients Over a 4 Year Period
Current Drug Therapy Going 3D – Cell Culture Approaches for Stem Cell Research and Therapy
Current Tissue Engineering (Discontinued) Cytochrome P450 Retinoic Acid 4-Hydroxylase Inhibitors: Potential Agents for Cancer Therapy
Mini-Reviews in Medicinal Chemistry Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy
Current Pharmaceutical Design Hypoxia: Targeting the Tumour
Anti-Cancer Agents in Medicinal Chemistry State of the Art of the Therapeutic Perspective of Sorafenib Against Hematological Malignancies
Current Medicinal Chemistry How Recent Advances in High-risk Myelodysplastic Syndrome Physiopathology May Impact Future Treatments
Current Pharmaceutical Design MUC Glycoproteins: Potential Biomarkers and Molecular Targets for Cancer Therapy
Current Cancer Drug Targets Implications of FLT3 Mutations in the Therapy of Acute Myeloid Leukemia
Reviews on Recent Clinical Trials Potential Beneficial Effects of Garlic in Oncohematology
Mini-Reviews in Medicinal Chemistry A Structure-Function Perspective of Jak2 Mutations and Implications for Alternate Drug Design Strategies: The Road not Taken
Current Medicinal Chemistry The Use of Growth Factors in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design siRNA-Mediated Knock-Down of P-Glycoprotein Expression Reveals Distinct Cellular Disposition of Anticancer Tyrosine Kinases Inhibitors
Drug Metabolism Letters Cyclophilin function in Cancer; lessons from virus replication
Current Molecular Pharmacology Some Implications of Receptor Kinase Signaling Pathway for Development of Multitargeted Kinase Inhibitors
Current Radiopharmaceuticals LRP/LR as an Alternative Promising Target in Therapy of Prion Diseases, Alzheimers Disease and Cancer
Infectious Disorders - Drug Targets Drugging Cell Cycle Kinases in Cancer Therapy
Current Drug Targets